Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years, of any gender
• People who have not yet received any treatment (systemic or local) for their cancer
• People with a confirmed diagnosis of squamous cell carcinoma of the esophagus at a specific stage (stages II to IVA, or stage IVB with cancer spread only to lymph nodes near the collarbone), where surgery has not been performed or has been declined
• People with a good general physical functioning level, rated 0 or 1 on a standard medical scale (meaning able to carry out most daily activities)
• People with a life expectancy of at least 3 months
• People whose major organs (such as kidneys, liver, and heart) are functioning well enough to meet the trial's requirements
• People who are able to have children and who agree to use contraception throughout the trial and for six months after the last dose of the study treatment
• People who are willing to voluntarily join the study, sign a consent form, follow the study requirements, and attend follow-up visits

Who may not be able to join:

• People who are underweight (BMI below 18.5 kg/m²) or who have lost 10% or more of their body weight in the two months before screening
• People whose esophageal cancer has significantly grown into nearby organs (such as the aorta or windpipe), or who have large, deep ulcers that carry a high risk of bleeding or forming abnormal connections between body cavities, or who have had an esophageal perforation or such a connection form within the past 6 months
• People who have previously received immunotherapy treatment
• People who have taken another experimental drug or participated in another interventional clinical trial within the 4 weeks before starting the study treatment
• People who have received or plan to receive a preventive vaccine or a live attenuated vaccine within 4 weeks before the first dose
• People who have been taking corticosteroid (steroid) medications within 2 weeks before the first dose
• People who have previously had an organ or tissue transplant, or a bone marrow/stem cell transplant from a donor
• People with an active, known, or suspected autoimmune disease (a condition where the immune system attacks the body's own tissues)
• People with uncontrolled heart-related symptoms or conditions
• People with a serious active or uncontrolled infection (rated grade 2 or higher on a standard medical severity scale)
• People with active tuberculosis (TB) or a history of active TB within the past 12 months
• People with a history of interstitial lung disease (a type of lung scarring condition) — with a specific exception that the trial site can clarify — or a history of non-infectious lung inflammation
• People with active hepatitis B or hepatitis C infection, a positive HIV test, or a known diagnosis of AIDS
• People who have had another type of cancer within the past 5 years — with some possible exceptions, such as certain types of early-stage skin cancer or prostate cancer, that the trial site can clarify
• People with a known allergy or sensitivity to any of the study drugs or their ingredients
• People with other serious physical or mental health conditions, or abnormal test results, that in the trial doctor's judgment could increase the risks of participating or affect the trial's results

Important: Always verify eligibility with the trial site directly before applying.